ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
ENDRA Life Sciences Inc. (NDRA) filed this Current Report on Form 8-K on July 9, 2025. The filing relates to the submission of a Registration Statement on Form S-1 for a public offering of common stock and warrants. The report references preliminary unaudited estimated financial results for the fiscal quarter ended June 30, 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These preliminary estimated results are contained within Exhibit 99.1 (Excerpt from Prospectus), which is referenced but not included in the provided text.
Material Changes
No material changes to financial performance versus prior periods are detailed in the text of this filing. The document serves to announce the filing of the offering prospectus rather than to report specific operational changes.
Guidance, Outlook, and Risks
The Company is proceeding with a public offering of common stock and warrants. The filing explicitly states that the financial information furnished in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Excerpt from Prospectus) for the specific preliminary unaudited financial results for the quarter ended June 30, 2025.
- Verify the terms of the proposed public offering of common stock and warrants in the full Form S-1 (No. 333-288575).
- Confirm the status of the offering and any subsequent updates to the prospectus.